Vizamyl

This launch strategy aims to drive revenue growth and establish Vizamyl as the leading amyloid PET tracer. Deployed under the "More to Discover" campaign, this high-impact brand activation addresses a critical challenge: up to 20% of amyloid PET scans are difficult to interpret. The campaign bridges the gap between imaging specialists and neurologists by driving key behavioral changes.
For radiologists and nuclear medicine specialists who know Vizamyl but do not use it, the campaign encourages a switch to alleviate pain points related to the time and patient workloads caused by equivocal scans. For referrers unfamiliar with the brand, the campaign prompts them to explicitly prescribe Vizamyl to prevent confusion during difficult interpretations and ensures patients receive the correct treatment plan.
By highlighting the core differentiator—that there is "more to discover" with Vizamyl—the campaign builds emotional connection and long-term brand recall. It leverages Vizamyl’s unique, FDA-approved attributes, which include:
Five read-regions, including the striatum for atrophy cases
A full-color read for better visualization
PiB derivation for proven reliability]
Supported by a comprehensive suite of marketing collateral, the campaign successfully demonstrates how Vizamyl delivers ultimate clarity for even the most complex cases.